- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00470171
Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis (URSONASH)
Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis
This is a phase II study with direct individual benefit. It is a randomized, double blind placebo controlled study whose aim is to evaluate the efficacy and tolerance of ursodesoxycholic acid in patients who have been diagnosed with non-alcoholic steatohepatitis.
The hepatoprotective effects of ursodesoxycholic acid may ameliorate the hepatic impairment associated with non-alcoholic steatohepatitis leading to subsequent significant decreases in transaminase elevations and non-invasive markers for hepatic fibrosis A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.
The duration of the study will be 12 months. An end of treatment evaluation (EoT) will take place at the end of the 12th month of treatment.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- La Pitié Salpêtrière Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Greater than 18 years of age.
- Hepatic biopsy consistent with non-alcoholic steatohepatitis: presence of >20% steatosis associated with hepatocyte swelling and/or intralobular necrosis within the last 18 months.
- Serum levels of ALAT and/or ASAT > 50 UI/L at the time of screening (with at least 3 elevated transaminase values within the last 12 months).
Exclusion Criteria:
- Hepatic biopsy not performed within the last 18 months.
- A single normal transaminase value within the last 12 months.
- Treatment with ursodesoxycholic acid within the last 12 months.
- Loss of more than 15% body weight between the time of the liver biopsy and the time of screening.
- Alcohol consumption of >20 g/day for women and > 30 g/day for men
- Hepatitis from other causes: chronic viral hepatitis B or C, elevated ferritin levels associated with C282Y homozygosity, primary biliary cirrhosis, primary sclerosing cholangitis, well documented auto-immune hepatitis (specific autoantibodies, hypergammaglobulinemia, consistent histologic changes), alpha1 antitrypsin deficiency, Wilson's disease, HIV infection.
- NASH from secondary causes: long term amiodarone administration, corticosteroid therapy, anti-obesity surgery within the last 2 years, tamoxifen.
- Child's type B or C cirrhosis.
- Presence of hepatocellular carcinoma.
- Treatment with rosiglitazone or pioglitazone currently or during the 3 preceding years, treatment with Vitamin E within the 6 months prior to screening.
- Women who are pregnant or nursing.
- Unavailability of hepatic biopsy slides for centralized interpretation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vlad Ratziu, M.D., Ph.D., La Pitié Salpétrière Hospital, Paris, France
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- URSONASH05-01
- EudraCT n° : 2005-001931-31
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Serum Levels of ALAT Transaminases
-
Nutrition Institute, SloveniaNational Institute of Public Health, Slovenia; Slovenian Research Agency; Higher...Enrolling by invitationVitamin D Serum LevelsSlovenia
-
Nutrition Institute, SloveniaSlovenian Research Agency; Valens Int. d.o.o., Slovenija; VIST - Faculty of Applied...CompletedVitamin D Serum LevelsSlovenia
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS)CompletedGamma Tocopherol Serum LevelsUnited States
-
American Medical Academy, SerbiaCompleted
-
AGUNCO Obstetrics and Gynecology CentreCompletedLow Serum Testosterone Levels in ManItaly
-
Camillians Saint Mary's Hospital LuodongUnknownOther Nonspecific Abnormal Serum Enzyme LevelsTaiwan
-
Rush University Medical CenterZimmer BiometActive, not recruitingSerum Metal Levels, Specifically Cobalt, Chromium, and TitaniumUnited States
-
Cairo UniversityCompletedFrozen Embryo Transfer | Progesterone Supplementation | Serum Progesterone Levels | Clinical Pregnancy Rates | Ongoing Pregnancy RatesEgypt
-
Near East University, TurkeyCompletedHealthy Postmenopausal Women | Serum CNP Levels | Healthy Reproductive Age Women | Healthy Perimenopausal WomenCyprus
-
University of TorontoRyerson University; George Brown CollegeCompleted
Clinical Trials on Ursodesoxycholic acid
-
Russell SwerdlowCompleted
-
Vanderbilt UniversityNational Cancer Institute (NCI)CompletedColorectal Adenomatous PolypsUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedHealthy VolunteersBelgium
-
Société des Produits Nestlé (SPN)Completed
-
Dr. Falk Pharma GmbHRecruiting
-
Leeds Beckett UniversityNot yet recruitingRheumatoid Arthritis | Muscle Atrophy
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States
-
University Hospital, Basel, SwitzerlandCompleted
-
Hadassah Medical OrganizationCompletedThrombocytopenia